Nature10mon
The antibody–drug conjugate renaissance
To overcome these hurdles, researchers are exploring next-generation ADC designs incorporating novel payloads, modified antibody backbones and new drug linker-release mechanisms. This is a ...
pharmaphorum2d
FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag
The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set ... as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies ...
Targeted Oncology13h
FDA Advances ALX2004 to Phase 1 Trials in EGFR+ Solid Tumors
The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...
technologynetworks18d
How AI and Spatial Biomarkers Are Transforming Antibody–Drug Conjugate Development
Spatial biomarkers are redefining ADC development by addressing critical challenges in understanding tumor biology and drug mechanisms. Armed with advanced AI-driven tools and informed by the spatial ...
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...
MyChesCo on MSN6d
Navrogen Advances Antibody Technology to Combat Cancer with New Findings
Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) ...
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated ...